-
First Canadian patient receives gene therapy post-approval
Montreal, May 20, 2026 – The first Canadian patient received HEMGENIX, gene therapy for hemophilia B (following regulatory approval and commercialization), in London, Ontario, on May 13. Several other...
New publication, Key Developments in Novel Therapies for Bleeding Disorders
The CHS, in collaboration with the Irish Haemophilia Society, is producing a new print publication, Key Developments in Novel Therapies for Bleeding Disorders. It is intended for a general...
British Columbia, Ontario approve access to gene therapy for hemophilia B
Montreal – April 3, 2026 – In the last few weeks, British Columbia and Ontario have approved access to HEMGENIX, gene therapy for hemophilia B. Decisions in other provinces...
Honouring the Life and Legacy of Marion Stolte
By Sarah Ford The Canadian bleeding disorders community mourns the passing of longtime volunteer and advocate Marion Stolte, whose dedication and leadership helped improve the lives of people living...
